Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung

Zusammenfassung

Hintergrund Für das fortgeschrittene hepatozelluläre Karzinom steht uns seit Kurzem ein deutlich erweitertes Spektrum an systemischen Therapieoptionen zur Verfügung. Insbesondere mit den immunonkologischen Kombinationstherapien können mittlerweile beeindruckende Ansprechraten und ein deutlich verlängertes Überleben bei insgesamt guter Verträglichkeit erreicht werden. Dabei werden diese Immun-Onkologie (IO)-basierten Kombinationen nicht nur zur Therapie des fortgeschrittenen HCC geprüft, sondern zunehmend auch in früheren Stadien im Sinne von periinterventionellen Therapiekonzepten und auch zum down-sizing zu lokalen Therapien. Im Kontext der Lebertransplantation (LTx) muss allerdings eine besonders kritische Nutzen-Risiko-Abwägung vor Einsatz von Immuntherapeutika im Rahmen multimodaler Konzepte erfolgen, da durch die Immuntherapie das Risiko einer potenziell letalen Abstoßung signifikant gesteigert werden kann.

Methode Diese Übersichtsarbeit basiert auf einer selektiven Literaturrecherche, die zwischen Dezember 2020 und April 2021 in den Datenbanken PubMed und Cochrane Library durchgeführt wurde. Leitlinien, Expertenmeinungen und Empfehlungen von Fachgesellschaften wurden besonders berücksichtigt.

Ergebnisse Fast jede fünfte LTx in Deutschland erfolgt aufgrund eines HCC (DSO Jahresbericht 2019). Die LTx ist dabei eine kurative Therapieoption nicht nur für die zugrunde liegende Lebererkrankung, sondern auch für den malignen Tumor. Einzelfallbeschreibungen weisen darauf hin, dass auch eine IO-Therapie vor einer LTx das Risiko einer Abstoßung bzw. eines Leberversagens bei einer nachfolgenden LTx erhöhen kann. Seit ca. 2015 werden Immuntherapeutika vielfach auch zur Tumortherapie bei Patienten nach einer LTx eingesetzt. In kleinen Fallserien wurden dabei Abstoßungsraten von 36%, die mit einer abstoßungsbedingten Mortalität von 20% der behandelten Patienten einhergingen, beschrieben. Eine ähnliche Inzidenz von Abstoßungsreaktionen wurde auch nach dem Einsatz von Immuntherapeutika bei Patienten nach anderen Organtransplantationen beschrieben.

Schlussfolgerung Im Zusammenhang mit einer Organtransplantation besteht durch eine IO-Therapie das Risiko einer Transplantatabstoßung, welches zum Verlust des Transplantates und auch zum Tod des Patienten führen kann. Unter Abwägung der oben dargelegten Überlegungen kann aber nach unserer sorgfältigen Nutzen-Risiko-Abwägung aus heutiger Sicht ein Einsatz einer IO-basierten Therapie im Kontext der Organtransplantation erfolgen.

Abstract

Background Multiple systemic therapy options have been recently approved for the treatment of hepatocellular carcinoma (HCC). In particular, immuno-oncology combination therapies can now achieve impressive response rates and significantly prolonged survival with good tolerability. These immuno-oncology (IO)-based combinations are currently not only evaluated for the therapy of advanced HCC, but increasingly also in earlier stages in terms of peri-interventional therapy concepts and also for down-sizing to local therapies. In the context of liver transplantation (LTx), a particularly critical benefit/risk assessment must be made before the use of immunotherapeutics in the context of multimodal concepts, since the risk of a potentially lethal rejection can be significantly increased by immunotherapy.

Methods This review is based on a selective literature search performed between December 2020 and April 2021 in the PubMed and Cochrane Library databases. Guidelines, expert opinions, and recommendations from professional societies were given special consideration.

Results Nearly one in five LTx in Germany are performed due to HCCs. In this context, LTx is a curative therapy option not only for the underlying liver disease but also for the malignant tumor. Individual case reports indicate that IO therapy prior to LTx may increase the risk of rejection or liver failure after subsequent liver transplantation. Since 2015, immunotherapeutics have also been widely used for tumor therapy in patients after LTx. In small case series, rejection rates of 36%, associated with rejection-related mortality of 20% of treated patients, have been described. A similar incidence of rejection has also been described following the use of immunotherapeutics in patients after other organ transplantations.

Conclusion In the context of organ transplantation, IO therapy carries the risk of graft rejection, which can lead to graft loss and also patient death. However, from today’s point of view, IO-based therapy can be considered in the context of organ transplantation with a careful benefit/risk assessment.

Schlüsselwörter

Nivolumab - Pembrolizumab - Ipilimumab - Rejektion - Transplantatversagen

Keywords

Nivolumab - Pembrolizumab - Ipilimumab - rejection - transplant failure

Publication History

Received: 13 May 2021

Accepted after revision: 14 September 2021

Article published online:
20 October 2021

• Literatur

• 1 Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 2021; DOI: 10.1080/14737140.2021.1882855. (PMID: 33499684)
• 2 Finn RS, Qin S, Ikeda M. et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2021; 39: 267-267 DOI: 10.1200/JCO.2021.39.3_suppl.267.
• 3 Vogel A, Martinelli E. [e-mail] EGCEa. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 2021; DOI: 10.1016/j.annonc.2021.02.014.
• 4 [Anonym]. Konsultationsfassung S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. 2021
• 5 Pommergaard HC, Rostved AA, Adam R. et al. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer 2020; 9: 455-467 DOI: 10.1159/000507397. (PMID: 32999871)
• 6 Abdel-Wahab N, Safa H, Abudayyeh A. et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7: 106 DOI: 10.1186/s40425-019-0585-1. (PMID: 30992053)
• 7 Friend BD, Venick RS, McDiarmid SV. et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatric blood & cancer 2017; 64 DOI: 10.1002/pbc.26682. (PMID: 28643391)
• 8 Delyon J, Zuber J, Dorent R. et al. Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge. Transplantation 2021; 105: 67-78 DOI: 10.1097/TP.0000000000003292. (PMID: 32355121)
• 9 Gassmann D, Weiler S, Mertens JC. et al. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. Transplant Direct 2018; 4: e376 DOI: 10.1097/TXD.0000000000000814. (PMID: 30255136)
• 10 Zhuang L, Mou HB, Yu LF. et al. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020; 19: 91-93 DOI: 10.1016/j.hbpd.2019.09.011. (PMID: 31706859)
• 11 Tio M, Rai R, Ezeoke OM. et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer 2018; 104: 137-144 DOI: 10.1016/j.ejca.2018.09.017. (PMID: 30347289)
• 12 Tsung I, Worden FP, Fontana RJ. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. The oncologist 2021; 26: 133-138 DOI: 10.1002/onco.13539. (PMID: 32969143)
• 13 Morales RE, Shoushtari AN, Walsh MM. et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015; 3: 22 DOI: 10.1186/s40425-015-0066-0. (PMID: 26082835)
• 14 Varkaris A, Lewis DW, Nugent FW. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. Am J Gastroenterol 2017; 112: 1895-1896 DOI: 10.1038/ajg.2017.387. (PMID: 29215617)
• 15 Rammohan A, Reddy MS, Farouk M. et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?. Hepatology 2018; 67: 1166-1168 DOI: 10.1002/hep.29575. (PMID: 29023959)
• 16 Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. J Immunother 2015; 38: 211 DOI: 10.1097/CJI.0000000000000077. (PMID: 25962109)
• 17 Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res 2018; 28: 61-64 DOI: 10.1097/CMR.0000000000000410. (PMID: 29140833)
• 18 Amjad W, Kotiah S, Gupta A. et al. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. J Clin Exp Hepatol 2020; 10: 185-187 DOI: 10.1016/j.jceh.2019.11.009. (PMID: 32189935)
• 19 DeLeon TT, Salomao MA, Aqel BA. et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 2018; 9: 1054-1062 DOI: 10.21037/jgo.2018.07.05. (PMID: 30603124)
• 20 Schvartsman G, Perez K, Sood G. et al. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma. Ann Intern Med 2017; 167: 361-362 DOI: 10.7326/L17-0187. (PMID: 28761949)
• 21 Mazzaferro V, Llovet JM, Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 DOI: 10.1016/S1470-2045(08)70284-5. (PMID: 19058754)
• 22 Mazzaferro V, Citterio D, Bhoori S. et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21: 947-956 DOI: 10.1016/S1470-2045(20)30224-2. (PMID: 32615109)
• 23 Choi HJ, Kim DG, Na GH. et al. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol 2013; 19: 4737-4744 DOI: 10.3748/wjg.v19.i29.4737. (PMID: 23922471)
• 24 Mehta N, Bhangui P, Yao FY. et al. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104: 1136-1142 DOI: 10.1097/TP.0000000000003174. (PMID: 32217938)
• 25 Schnitzbauer AA, Filmann N, Adam R. et al. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Ann Surg 2020; 272: 855-862 DOI: 10.1097/SLA.0000000000004280. (PMID: 32889867)
• 26 Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol 2015; 62: S170-185 DOI: 10.1016/j.jhep.2015.02.042. (PMID: 25920086)
• 27 Gul-Klein S, Kastner A, Haber PK. et al. Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. J Hepatocell Carcinoma 2021; 8: 133-143 DOI: 10.2147/JHC.S292010. (PMID: 33777855)
• 28 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977 DOI: 10.1002/hep.27752. (PMID: 25689978)
• 29 Mehta N, Dodge JL, Grab JD. et al. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020; 71: 943-954 DOI: 10.1002/hep.30879. (PMID: 31344273)
• 30 Shi XL, Mancham S, Hansen BE. et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. J Hepatol 2016; 64: 1274-1282 DOI: 10.1016/j.jhep.2016.02.034. (PMID: 26941095)
• 31 Esfahani K, Al-Aubodah TA, Thebault P. et al. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun 2019; 10: 4712 DOI: 10.1038/s41467-019-12628-1. (PMID: 31624262)
• 32 Aguirre LE, Guzman ME, Lopes G. et al. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. The oncologist 2019; 24: 394-401 DOI: 10.1634/theoncologist.2018-0195. (PMID: 30413665)
• 33 Fisher J, Zeitouni N, Fan W. et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020; 82: 1490-1500 DOI: 10.1016/j.jaad.2019.07.005. (PMID: 31302190)
• 34 Shi GM, Wang J, Huang XW. et al. Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transpl 2021; 27: 444-449 DOI: 10.1002/lt.25887. (PMID: 32897657)
• 35 Nordness MF, Hamel S, Godfrey CM. et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. Am J Transplant 2020; 20: 879-883 DOI: 10.1111/ajt.15617. (PMID: 31550417)
• 36 Chen GH, Wang GB, Huang F. et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol 2021; 66: 101386 DOI: 10.1016/j.trim.2021.101386. (PMID: 33744409)
• 37 Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation. Am J Transplant 2020; DOI: 10.1111/ajt.16448. (PMID: 33316117)
• 38 Schrem H, Kurok M, Kaltenborn A. et al. Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl 2013; 19: 1252-1261 DOI: 10.1002/lt.23722. (PMID: 24106037)
• 39 Zhu AX, Kudo M, Assenat E. et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67 DOI: 10.1001/jama.2014.7189. (PMID: 25058218)
• 40 Pinato DJ, Kaseb A, Wang Y. et al. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 2020; 8 DOI: 10.1136/jitc-2020-000726. (PMID: 33028690)
• 41 Hutchinson JA, Kronenberg K, Riquelme P. et al. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nat Commun 2021; 12: 1439 DOI: 10.1038/s41467-021-21572-y. (PMID: 33664251)